GSK PLC Sponsored ADR $GSK Holdings Raised by Vise Technologies Inc.

Vise Technologies Inc. raised its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 17.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 162,248 shares of the pharmaceutical company’s stock after buying an additional 24,123 shares during the quarter. Vise Technologies Inc.’s holdings in GSK were worth $7,815,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD grew its holdings in shares of GSK by 1.1% during the 3rd quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company’s stock worth $239,210,000 after purchasing an additional 55,116 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after purchasing an additional 852,437 shares during the period. Foster Victor Wealth Advisors LLC raised its stake in GSK by 5.8% in the third quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company’s stock valued at $21,674,000 after purchasing an additional 23,934 shares in the last quarter. Sound Income Strategies LLC raised its stake in GSK by 2.7% in the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock valued at $16,209,000 after purchasing an additional 9,218 shares in the last quarter. Finally, Waverly Advisors LLC raised its stake in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after purchasing an additional 270,863 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Down 0.8%

Shares of GSK opened at $49.11 on Tuesday. GSK PLC Sponsored ADR has a 52-week low of $45.81 and a 52-week high of $61.69. The business’s fifty day moving average is $49.37 and its 200-day moving average is $52.34. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The firm has a market cap of $99.34 billion, a price-to-earnings ratio of 10.26, a PEG ratio of 2.12 and a beta of 0.33.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be paid a $0.4518 dividend. This represents a $1.81 annualized dividend and a yield of 3.7%. This is a boost from GSK’s previous quarterly dividend of $0.4515. The ex-dividend date of this dividend is Friday, November 13th. GSK’s payout ratio is 61.46%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GSK. Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Wolfe Research began coverage on shares of GSK in a report on Friday, October 9th. They issued an “outperform” rating and a $70.00 target price on the stock. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup started coverage on shares of GSK in a report on Friday, July 24th. They set a “neutral” rating for the company. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of GSK in a report on Sunday, August 2nd. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $56.30.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.